Cooperative development of antimicrobials: Looking back to look ahead

Nature Reviews Microbiology

Volumn 13, Issue 10, 2015, Pages 651-657

  Nathan, Carl ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; CHLOROQUINE; PENICILLIN DERIVATIVE; PRIMAQUINE; PROGUANIL; QUININE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INFORMATION; GOAL ATTAINMENT; GOVERNMENT REGULATION; HUMAN; INVESTMENT; MALARIA; MEDICAL SOCIETY; PATENT; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; COOPERATION; EUROPE; HISTORY; ORGANIZATION AND MANAGEMENT; PROCEDURES; PUBLIC RELATIONS; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIMALARIALS; ANTITUBERCULAR AGENTS; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; EUROPE; HISTORY, 20TH CENTURY; INTERINSTITUTIONAL RELATIONS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; UNITED STATES;

EID: 84942009967     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3523     Document Type: Review

References (33)

1. Nathan, C., Cars, O. Antibiotic resistance-problems, progress, and prospects. New Engl. J. Med. 371, 1761-1763 (2014).
2. O'Neill, J. C. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance [online], http://amr-review. org/sites/default/files/AMR Review Paper-Tackling a crisis for the health and wealth of nations-1.pdf (2014).
3. Nathan, C. Antibiotics at the crossroads. Nature 431, 899-902 (2004).
4. Lax, E. The Mould in Dr Florey's Coat: the Remarkable True Story of Penicillin (Little, Brown & Co., 2004).
5. Abraham, E. P., Chain, A. Purification of penicillin. Nature 149, 328-328 (1942).
6. Abraham, E. P. et al. Further observations on penicillin. Lancet 238, 177-189 (1941).
7. Chain, E. et al. Penicillin as a chemotherapeutic agent. Lancet 236, 226-228 (1940).
8. Swann, J. P. The search for synthetic penicillin during World War II. Br. J. Hist. Sci. 16, 154-190 (1983).
9. Rasmussen, N. Of "small men", big science and bigger business: the Second World War and biomedical research in the United States. Minerva 40, 115-146 (2002).
10. Brown, K. Penicillin Man: Alexander Fleming and the Antibiotic Revolution (Sutton Publishing, 2004).
11. Lockwood, J. S. War-time activities of the National Research Council and the Committee on Medical Research: with particular reference to team-work on studies of wounds and burns. Ann. Surg. 124, 314-327 (1946).
12. Keefer, C. S. et al. Penicillin in the treatment of infections. A report of 500 cases. JAMA 122, 1217-1224 (1943).
13. Richards, A. N. Penicillin. Statement released by the Committee on Medical Research. JAMA 122, 235-236 (1943).
14. Sheehan, J. C., Henery-Logan, K. R. The total synthesis of penicillin V. J. Am. Chem. Soc. 79, 1262-1263 (1957).
15. Coggeshall, L. T. et al. Research work on chemotherapy. Science 192, 176-178 (1940).
16. Masterson, K. M. The Malaria Project: The U.S. Government's Secret Mission to Find a Miracle Cure (New American Library, 2014).
17. Slater, L. B. War and Disease (Rutgers Univ. Press, 2014).
18. Coatney, G. R. Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. 12, 121-128 (1963).
19. World Health Organization. Making a difference: 30 years of research and capacity building in tropical diseases. WHO [online], http://whqlibdoc.who.int/publications/2007/9789241595575-eng.pdf (2007).
20. Bathurst, I., Hentschel, C. Medicines for Malaria Venture: sustaining antimalarial drug development. Trends Parasitol. 22, 301-307 (2006).
21. O'Brien, S. Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry. Br. J. Clin. Pharmacol. 79, 168-172 (2015).
22. Rex, J. H. ND4BB: addressing the antimicrobial resistance crisis. Nat. Rev. Microbiol. 12, 231-232 (2014).
23. Stavenger, R. A., Winterhalter, M. TRANSLOCATION project: how to get good drugs into bad bugs. Sci. Transl. Med. 6, 228ed7 (2014).
24. Chakraborty, S. et al. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339, 88-91 (2013).
25. Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159-167 (2014).
26. Kim, J. H. et al. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc. Natl Acad. Sci. USA 110, 19095-19100 (2013).
27. Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010).
28. Morel, C. M., Mossialos, E. Stoking the antibiotic pipeline. BMJ 340, c2115 (2010).
29. Nathan, C. Aligning pharmaceutical innovation with medical need. Nat. Med. 13, 304-308 (2007).
30. Nathan, C. Fresh approaches to anti-infective therapies. Sci. Transl. Med. 4, 140sr2 (2012).
31. Payne, D. J., Gwynn, M. N., Holmes, D. J., Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
32. Projan, S. J. Why is big Pharma getting out of antibacterial drug discovery Curr. Opin. Microbiol. 6, 427-430 (2003).
33. Van Boekel, T. P. et al. Global trends in antimicrobial use in food animals. Proc. Natl Acad. Sci. USA 112, 5649-5654 (2015).